Epigenetic Mechanisms Involved in Differential MDR1 MRNA Expression Between Gastric and Colon Cancer Cell Lines and Rationales for Clinical Chemotherapy

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2008 Aug 5

PMID 18673531

Citations 15

Authors

Tae-Bum Lee

Jung-Hee Park

Young-Don Min

Kyung-Jong Kim

Cheol-Hee Choi

Affiliations

Soon will be listed here.

Abstract

Background: The membrane transporters such as P-glycoprotein (Pgp), the MDR1 gene product, are one of causes of treatment failure in cancer patients. In this study, the epigenetic mechanisms involved in differential MDR1 mRNA expression were compared between 10 gastric and 9 colon cancer cell lines.

Methods: The MDR1 mRNA levels were determined using PCR and real-time PCR assays after reverse transcription. Cytotoxicity was performed using the MTT assay. Methylation status was explored by quantification PCR-based methylation and bisulfite DNA sequencing analyses.

Results: The MDR1 mRNA levels obtained by 35 cycles of RT-PCR in gastric cancer cells were just comparable to those obtained by 22 cycles of RT-PCR in colon cancer cells. Real-time RT-PCR analysis revealed that MDR1 mRNA was not detected in the 10 gastric cancer cell lines but variable MDR1 mRNA levels in 7 of 9 colon cancer cell lines except the SNU-C5 and HT-29 cells. MTT assay showed that Pgp inhibitors such as cyclosporine A, verapamil and PSC833 sensitized Colo320HSR (colon, highest MDR1 expression) but not SNU-668 (gastric, highest) and SNU-C5 (gastric, no expression) to paclitaxel. Quantification PCR-based methylation analysis revealed that 90% of gastric cancer cells, and 33% of colon cancer cells were methylated, which were completely matched with the results obtained by bisulfite DNA sequencing analysis. 5-aza-2'-deoxcytidine (5AC, a DNA methyltransferase inhibitor) increased the MDR1 mRNA levels in 60% of gastric cells, and in 11% of colon cancer cells. Trichostatin A (TSA, histone deacetylase inhibitor) increased the MDR1 mRNA levels in 70% of gastric cancer cells and 55% of colon cancer cells. The combined treatment of 5AC with TSA increased the MDR1 mRNA levels additively in 20% of gastric cancer cells, but synergistically in 40% of gastric and 11% of colon cancer cells.

Conclusion: These results indicate that the MDR1 mRNA levels in gastric cancer cells are significantly lower than those in colon cancer cells, which is at least in part due to different epigenetic regulations such as DNA methylation and/or histone deacetylation. These results can provide a better understanding of the efficacy of combined chemotherapy as well as their oral bioavailability.

Citing Articles

Dual targeting of CXC chemokine receptor 4 and multidrug resistance protein 1 by ZIN056 effectively combat daunorubicin resistance in acute myeloid leukemia cells.

Abohassan M, Al Shahrani M, AlOuda S, Rajagopalan P Med Oncol. 2025; 42(4):106.

PMID: 40080290 DOI: 10.1007/s12032-025-02656-x.

ANXA9 as a novel prognostic biomarker associated with immune infiltrates in gastric cancer.

Zhang T, Yu S, Zhao S PeerJ. 2022; 9:e12605.

PMID: 35003923 PMC: 8684324. DOI: 10.7717/peerj.12605.

Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

You D, Richardson J, Aleksunes L Drug Metab Dispos. 2020; 48(6):459-480.

PMID: 32193359 PMC: 7250367. DOI: 10.1124/dmd.119.089953.

Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma.

Tomiyasu H, Tsujimoto H Vet Sci. 2017; 2(3):185-205.

PMID: 29061940 PMC: 5644633. DOI: 10.3390/vetsci2030185.

Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity.

Khaleel S, Al-Abd A, Ali A, Abdel-Naim A Sci Rep. 2016; 6:36855.

PMID: 27841296 PMC: 5107943. DOI: 10.1038/srep36855.

References

Maliepaard M, van Gastelen M, de Jong L, Pluim D, van Waardenburg R, Floot B . Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999; 59(18):4559-63. View

Kantharidis P, El-Osta A, DeSilva M, Wall D, Hu X, Slater A . Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res. 1998; 3(11):2025-32. View

Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R . The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999; 128(2):403-11. PMC: 1571648. DOI: 10.1038/sj.bjp.0702807. View

Riordan J, Ling V . Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem. 1979; 254(24):12701-5. View

Takara K, Horibe S, Obata Y, Yoshikawa E, Ohnishi N, Yokoyama T . Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull. 2005; 28(1):138-42. DOI: 10.1248/bpb.28.138. View

Minderman H, OLoughlin K, Pendyala L, Baer M . VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res. 2004; 10(5):1826-34. DOI: 10.1158/1078-0432.ccr-0914-3. View

Choi C, Sun K, An C, Yoo J, Hahm K, Lee I . Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin). Biochem Biophys Res Commun. 2002; 295(4):832-40. DOI: 10.1016/s0006-291x(02)00755-6. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M . Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem. 1999; 262(3):924-32. DOI: 10.1046/j.1432-1327.1999.00469.x. View

10.

Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K . Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 1998; 92(11):4296-307. View

11.

Jin S, Scotto K . Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol. 1998; 18(7):4377-84. PMC: 109021. DOI: 10.1128/MCB.18.7.4377. View

12.

Lewis J, Meehan R, Henzel W, Jeppesen P, Klein F, Bird A . Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell. 1992; 69(6):905-14. DOI: 10.1016/0092-8674(92)90610-o. View

13.

Gupta N, Martin P, Miyauchi S, Ananth S, Herdman A, Martindale R . Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun. 2006; 343(2):571-7. DOI: 10.1016/j.bbrc.2006.02.172. View

14.

Baker E, Johnstone R, Zalcberg J, El-Osta A . Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005; 24(54):8061-75. DOI: 10.1038/sj.onc.1208955. View

15.

Hyafil F, Vergely C, du Vignaud P, Grand-Perret T . In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993; 53(19):4595-602. View

16.

Cordon-Cardo C, OBrien J, Boccia J, CASALS D, Bertino J, Melamed M . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38(9):1277-87. DOI: 10.1177/38.9.1974900. View

17.

Ho G, Moodie F, Satsangi J . Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut. 2003; 52(5):759-66. PMC: 1773632. DOI: 10.1136/gut.52.5.759. View

18.

van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B . Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002; 51(6):797-802. PMC: 1773491. DOI: 10.1136/gut.51.6.797. View

19.

Park J, Kramer B, Lai S, Goldstein L, Gazdar A . Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J Natl Cancer Inst. 1990; 82(3):193-8. DOI: 10.1093/jnci/82.3.193. View

20.

Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J . Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004; 15(12):1773-81. DOI: 10.1093/annonc/mdh473. View